Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Clinical Trial Details
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-Versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant (MODULAATE)
Complete Title: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-versus-Host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Trial Phase: II/III
Investigator: Masumi Ueda Oshima
This study is a Phase 2/3 prospective, double-blind, randomized, multi-center, placebo-controlled study for prevention of acute GVHD (aGVHD) in subjects undergoing an allogeneic hematopoietic cell transplant (HCT).
Keywords:
- Graft Versus Host Disease (GVHD)
- Immune System Diseases
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.
Adult
II/III
Masumi Ueda Oshima
RG1004024
NCT03805789
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-versus-Host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)
Graft Versus Host Disease (GVHD)
Immune System Diseases